necessary to protect them as soon as possible. However, the timing of this vaccination is governed by the amount of maternal antibody present and this I think is the most important single factor affecting the use and efficacy of vaccine.
The maternal antibody content of the chick is dependent on the vaccinal status of the parent flock or the flock's exposure to infection. Keeble & Wade (1963) proved that chicks from an unvaccinated or once vaccinated parent are capable of an adequate serological response when vaccinated at 10 days but in the case of chicks originating from a twice vaccinated parent the interval should be twenty-one days. It was therefore agreed that the first injection be given at 3 weeks of age. In certain cases where there was a high degree of risk vaccination was carried out at 10-14 days and repeated fourteen days later; however, with the passage of time the need for this double vaccination has ceased.
It was found from experience that to obtain a full level of protection in areas of heavy infection a triple vaccination programme should be carried out, namely at 21 days, 8-10 weeks and 16-20 weeks of age.
This programme is now advocated by most vaccine manufacturers and, if followed, gives satisfactory protection. Cases, however, do occur in allegedly vaccinated birds which on investigation prove to be vaccination failures.
Vaccination Failures
The chief causes of these are:
(1) Insufficient vaccination coverage: It was originally considered that a coverage of between 80 and 85 % was necessary for reasonable disease control, but the latter figure was in fact never achieved; 75 % coverage has produced satisfactory results and the aim has been to maintain this level. Table 1 shows that vaccine had been in use for two years before there was any appreciable effect on the incidence of disease.
The cost of vaccination is a very important item in the profitability of the poultry industry. There is a natural tendency when disease incidence is low for the use of vaccine in the area to decline. This has resulted in a build up of infection and flocks with waning immunity showing clinical disease. This is a situation which has to be guarded against by repeated reminders of the benefits of vaccination.
(2) Inefficient storage of vaccine: This can occur after vaccine has reached the poultry farmer and in some of the investigated cases vaccine had been kept in what amounted to practically hot-house conditions. In 1946, when all the military forces from overseas were returning home, this country experienced the greatest increase in paralytic poliomyelitis it had ever known. The incidence remained high until vaccination got the better of it and reduced the number of paralytic cases to fewer than 10 per year. The disease left many of its victims alive but paralysed and thus there was a high emotional force driving the virologists to find the best vaccine and vaccination schedule to eliminate it. After the development of a successful vaccine in America the Medical Research Council had no difficulties in obtaining volunteers to test British-Section ofComparative Medicine produced vaccine and these studies have been most fruitful (Medical Research Council 1957 . A systematic study of all the factors that may play a part in immunization was possible and many of the findings were fundamental to immunology, irrespective of the antigen used to eliminate the disease. It also had the built-in advantage of allowing studies of the responses of subjects to three closely related antigens given simultaneously.
The findings may be considered under three headings: (1) The antigenicity of the vaccine. (2) The influence of the immune state of the subject.
(3) The effect of vaccination on the disease.
Antigenicity ofthe Vaccine
The significant part that Jonas Salk played in the production of poliomyelitis vaccine was finding the correct concentration of formaldehyde that would kill poliomyelitis virus without destroying its antigenicity. Strains differed in the antigenicity and indeed there were marked differences in the antigenicity between the virus types. In 1961 Beale and his colleagues showed that injecting the same quantity of antigen (as measured by D antigen) of the different virus types into a monkey gave quite different levels of antibody response. Furthermore, the vaccine potency could be measured in guinea-pigs (Gard et al. 1956) or monkeys (Perkins 1957 ) and a typical dose/response relationship could be established. Once a level of antigenicity which was both commercially feasible and immunologically satisfactory had been selected it was logical to start studies in children.
Influence ofthe Immune State ofthe Subject
Initially there was a desire to protect the infant against poliomyelitis before any other immunization procedure was started. Investigations in neonatal infants immediately brought to light two inhibitory factors: the inhibition by maternal antibody, and the decreased ability of the young child to respond to an immunological stimulus.
Giving two doses of poliomyelitis vaccine to infants aged 1 week, 6 weeks or 10 weeks showed quite clearly (Perkins et al. 1958 ) that although satisfactory responses were obtained to the virus Type II component, not quite such satisfactory responses were obtained to the Type III component, and very disappointing responses were obtained to the Type I component. The older the child the better the responses and, although in many infants the primary responses were masked by the high titres of maternal antibody, the true immunological response was revealed at the time the reinforcing dose was given nine to twelve months later (Perkins et al. 1959a) .
In order to separate these two inhibitory factors, children with no maternal antibody (Perkins et al. 1959b ) and of different ages were selected for vaccination (Perkins et al. 1959c (Perkins et al. , 1961 and it was clearly shown that the older the child the better the responses for each virus type. Therefore, the only way of obtaining better antibody responses in the infants was to delay immunization until maternal antibody had fallen below inhibitory levels, to give a third dose of vaccine as part of the primary course of immunization, and to use a more potent vaccine either by increasing the antigen content or adding an adjuvant. All these suggestions were put to the test and all were able to increase the antibody response.
The availability of oral poliomyelitis vaccine made from the strains attenuated by Dr Sabin meant that a most interesting comparison of the responses of infants to these two vaccines could now be made (Hobson et al. 1962) .
In 3-month-old infants, in the majority of whom there was still circulating maternal antibody, the oral living vaccine gave a much better antibody response than the killed vaccine, especially to the Type I virus . It was also interesting to observe the effect of giving a single dose of Type I living virus vaccine to schoolchildren 12-16 years of age (Hoskins et al. 1963 ) all of whom had been given 3 doses of killed vaccine at least nine months before the oral living vaccine. In spite of only limited attempts at virus isolations, many were shown to excrete virus and in more than half of them there was a significant antibody rise. Even giving a single dose of living virus (Type II) to adults (18-45 years of age) showed a good colonization of the gut with good antibody responses (Hoskins et al. 1963 ).
Effect of Vaccination on the Disease
From these findings it would seem logical to use only living attenuated vaccine and not be bothered with the difficulties of using the killed vaccine given by the parenteral route. The one disadvantage of a living vaccine, however, is that if paralysis occurs in a vaccinated subject or a contact of a vaccinee it is almost impossible to determine whether paralysis was caused by the vaccine virus or a wild virus. There is a very low associated case rate (about 1 in a million) and in countries where poliomyelitis is still a problem this is a low price to pay for eradication of the disease.
In this country the incidence of paralytic poliomyelitis decreased as soon as immunization started but too few people volunteered to have the killed vaccine. It was not until the oral vaccine with its greater appeal of administration was used that the incidence of cases fell to the lowest levels for fifty years (23 cases in 1966 and 19 cases in 1967).
Sweden also has a very proud record. The incidence of poliomyelitis cases in Sweden fell to zero by 1965, since when it has remained at zero and there have been no isolations of the virus from fical samples taken from patients attending hospitals for other reasons. This excellent record has been achieved by giving only very potent killed vaccine to more than 90% of the population. If these two conditions are satisfied then the same goal can be achieved by any country using killed vaccine.
The lesson to be learnt from these extensive studies is that immunization should not start too eatly, giving time for the maternal antibody to fall to non-inhibitory titres as well as allowing the infant to increase his ability to respond to an antigenic stimulus. If a killed vaccine is used it must be highly antigenic and adequate stimulus must be given both in the number and in the spacing of doses. From the public health point of view the disease will be eliminated only if the majority of the population is immunized.
The decision concerning these factors must be taken by the national health authorities, balancing the possibility of risk against the prevalence and severity of the disease. Mr A D Campbell (Ministry ofAgriculture, Fisheries and Food, Bristol)
Swine Fever
It may truly be said, I think, that the branch of veterinary medicine which serves the livestock industry employs vaccination as a means by which the profitable production of food-producing animals may be achieved, in an environment where they are exposed to the damaging effects of specific pathogens.
To present this in its true context, I should emphasize that however possible, in scientific terms, the vaccinal protection of a community may be, little of practical worth will be achieved unless the scientific possibility can be related to an economic advantage for the industry. I should say also that, if the protection which a vaccine may afford seems to offer an immediate means of enhanced financial return to the livestock industry, the demand from the industry for vaccination is likely to be intolerant of any veterinary advocacy of caution concerning its use.
I should add that in circumstances where a specific infection involves the livestock industry in substantial continuing expense, either from illness and death of livestock or in the cost of preventing these, then, if complete eradication of that infection is a realistic possibility and the pievention of reinfection can be reasonably assured, the short-term expenditure of a large sum of money to achieve eradication may be well justified in economic terms by the freedom from continuing expense which will accrue.
It is a long-established precept of official veterinary circles in this country to be vigilant concerning methods of control of infectious disease, which might have the effect of denying the possibility of success to any campaign for the total eradication of that disease.
After a period of about a hundred years, during which time it was endemic in this country, swine fever was successfully eradicated from Great Britain in a campaign which lasted from March 1963 until June 1966. It was during this campaign and a similar one which is still being pursued in the United States that many of the problems associated with the use of swine fever vaccines were highlighted. In this country the use of swine fever vaccines is now prohibited by law.
De Schweinitz & Dorset (1903) showed the causal agent of swine fever to be a filterable virus, and Dorset introduced the method of simultaneous serum/virus immunization against the disease. This remained in common use in the United States until as recently as 1963, although it never found favour in this country as a method of immunization against swine fever. Dorset devoted much time to preparing and testing bloodorigin vaccines inactivated with different chemicals. His most encouraging results were obtained with those prepared from infected blood to which was added the dye crystal-violet, either alone or in combination with phenol. After his death, this work was continued and reported on by his colleagues McBryde & Cole (1936) .
Crystal-violet inactivated vaccine had an obvious appeal in those countries which are reluctant to allow the use of products containing live virus for the control of disease. In 1947,
